Skip to content
Clinical Trials – home

Agalsidase alfa Clinical Trials in Fabry Disease

0 / 1
trials open to patients / all trials
11+
Countries

In short

Clinical trials investigating agalsidase alfa are studying treatment in people with Fabry disease, including adults with heart involvement. These trials look at how well study treatments work and how safe they are, with a focus on heart measures such as left ventricular mass index. The target group in the available trial is male and female adults with Fabry disease and left ventricular hypertrophy.

Key points

  • Clinical trials investigating agalsidase alfa in the provided data focus on Fabry disease in adults. The main trial is a Phase 3 study in male and female adults with left ventricular hypertrophy, a form of heart muscle thickening. It compares study treatment with standard Fabry therapies and measures changes in left ventricular mass index over 18 months. The trial uses cardiac MRI, a detailed heart scan, to track heart changes. The study is authorised and plans to enroll 110 participants.

Trial overview

The available study is NCT05280548, an interventional Phase 3 trial in adults with Fabry disease. It is authorised and plans to enroll 110 participants. The study is designed to compare the effect of venglustat with standard of care Fabry therapies on heart changes over 18 months.

Who can participate

The trial includes male and female adult participants with Fabry disease. It specifically targets people with left ventricular hypertrophy, which means thickening of the main pumping chamber of the heart.

  • Adults only: the source data says the study is for adult participants.
  • Both men and women: the study includes male and female participants.
  • Fabry disease with heart involvement: the study focuses on people who already have left ventricular hypertrophy.

What is being measured

The main outcome is the slope of left ventricular mass index measured by cardiac magnetic resonance imaging, also called cardiac MRI. In simple terms, the study checks how the thickness or size of the heart muscle changes over time. The MRI images are read centrally, which means the scans are reviewed in one main place to keep the measurements consistent.

The study follows participants over 18 months. This time frame helps researchers see whether the heart measure improves, stays stable, or gets worse during the study period.

Treatments and comparators

The trial compares venglustat with standard of care Fabry therapies. The source data lists several treatment options used in the study context, including Replagal, Fabrazyme, and Galafold, along with venglustat.

  • Replagal is listed as an infusion treatment given through a vein.
  • Fabrazyme is also listed as an infusion treatment.
  • Galafold is listed as an oral treatment, which means taken by mouth.
  • venglustat is listed as an oral treatment in this study.

The trial title and summary show that the main goal is to compare study treatment with the usual Fabry treatments used in practice.

Trial phase and size

This is a Phase 3 study, which usually means the treatment is being tested in a larger group and compared with other available options. The planned enrollment is 110 participants. The study status is Authorised.

What the trial means for patients

This trial is focused on a heart-related problem in Fabry disease, not on the whole disease picture. The researchers are mainly asking whether the study treatment can change left ventricular mass index over time compared with standard Fabry therapies. Because the study includes adults of both sexes with heart muscle thickening, it is aimed at a specific patient group rather than all people with Fabry disease.

Questions people often ask

Conditions where Agalsidase alfa is being studied

Each condition opens its own overview and trial list

Trials with Agalsidase alfa

Recruiting trials first

See all 1 →
Quick filters
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.